EFFECTIVE HALF-LIFE, EXCRETION AND RADIATION EXPOSURE OF 177LU-PSMA

Simple item page
dc.contributor.authorParlak Y.
dc.contributor.authorMutevellzade G.
dc.contributor.authorSezgln C.
dc.contributor.authorGoksoy D.
dc.contributor.authorGumuser G.
dc.contributor.authorSaylt E.
dc.date.accessioned2024-07-22T08:02:38Z
dc.date.available2024-07-22T08:02:38Z
dc.date.issued2023
dc.description.abstractThe study aims to evaluate the radiation safety conditions by detecting the patient's urine excretion rate, calculating the effective half-life, and determining the retention of 177Lu-PSMA in the body. Urine samples of patients were collected for 24 hours (6, 12, 18, and 24 hours) following the infusion, excretion rate and retention of 177Lu-PSMA in the body of patients were calculated. The measurements of dose rate were performed. Effective half-life calculated from dose rate measurements was found as 18.5 ± 11 h within the first 24 h and 48.1 ± 22.8 h between 24 and 72 h. Excreted activity in urine was found as 33.8 ± 20.7, 40.4 ± 20.3, 46.1 ± 22.4, and 53.3 ± 21.5% of total doses at 6, 12, 18, and 24 h after administration, respectively. External dose rates for 4 h and 24 h were 24.51 μSv/h, 16.14 μSv/h, respectively. Our results showed that 177Lu-PSMA treatment was suitable for outpatient treatment in terms of radiation safety. © 2023 The Author(s).
dc.identifier.DOI-ID10.1093/rpd/ncad141
dc.identifier.issn01448420
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11946
dc.language.isoEnglish
dc.publisherOxford University Press
dc.subjectBody Fluids
dc.subjectHalf-Life
dc.subjectHumans
dc.subjectRadiation Exposure
dc.subjectRadioisotopes
dc.subjectRadiopharmaceuticals
dc.subjectLutetium-177
dc.subjectradioisotope
dc.subjectradiopharmaceutical agent
dc.subjectbody fluid
dc.subjecthalf life time
dc.subjecthuman
dc.subjectradiation exposure
dc.titleEFFECTIVE HALF-LIFE, EXCRETION AND RADIATION EXPOSURE OF 177LU-PSMA
dc.typeArticle

Files

Collections

Scopus Koleksiyonu